Vincerx Pharma and Oqory highlighted Phase 1a/1b data for OQY-3258 

It proposed a merger to advance OQY-3258 into global Phase 3 trials and build a differentiated ADC pipeline 

Currently, 3 trials are ongoing for it, Phase 1a/1b for solid tumors (NCT04892342), Phase 3 for HR+/HER2- breast cancer (NCT06383767) and TNBC (NCT06732323) with BTD from China’s NMPA

Data highlights presented at ESMO’ 24 for evaluable patient a)TNBC (Previously Untreated) ORR: 76%, DCR: 100%, mDOR/PFS: Not reached, Jan ’25 update (n=35): ORR improved to 80%; b)Late-Stage TNBC: ORR: 27%, DCR: 62%, 6-m DOR: 39% and PFS: 25%; c)HR+/HER2- Breast Cancer: ORR: 39%, DCR: 78%, 6-m DOR: 70% and PFS: 55%, mPFS: 7.4 m

OQY-3258 showed 41% intracranial ORR in patients with brain mets. PFS for brain mets: 4.6 m vs. 2.8 m

OQY-3258’s efficacy and favorable safety profile position it as a best-in-class anti-TROP2 ADC

The merger aims to accelerate OQY-3258’s development and build a next-gen ADC pipeline to address unmet patient needs